BY13

CAT: 0804-HY-176225Size: 1 EachDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-176225Size:1 Each

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR) ) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant. BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model[1]. Pink: SRC-3 ligand (SI-2) (HY-101447) ; Blue: CRBN ligase ligand (HY-41547) ; Black: linker (HY-176226)

UNSPSC

12352005

Target

Apoptosis; Estrogen Receptor/ERR; PROTACs; Src

Related Pathways

Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Smiles

C/C(C1=NC=CC=C1)=N\NC2=NC(C=CC=C3)=C3N2C4CN(C4)C5CCN(CC5)C6=CC=CC7=C6C(N(C7=O)C8C(NC(CC8)=O)=O)=O

Molecular Formula

C35H35N9O4

Molecular Weight

645.71

References & Citations

[1]Liang J, et al. Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer. J Med Chem. 2025 Jun 12; 68 (11) :11516-11542.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

ERα; SRC-3

Alternative Products

Catalog	Name
GTR19263295-01	BY13

BY13

Alternative Products

Popular Products